Plus   Neg

Thermo Fisher Acquires Novasep's Viral Vector Manufacturing Business For 725 Mln Euros

Thermo Fisher Scientific Inc. (TMO) has completed the acquisition of Henogen S.A., Groupe Novasep SAS's viral vector manufacturing business in Belgium for about 725 million euros in cash, the two companies said Friday.

Novasep's viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies as well as large biopharma customers. The business will be part of Thermo Fisher's Pharma Services business within the Laboratory Products and Services Segment.

Novasep's viral vector business has two locations in Seneffe and Gosselies, Belgium. It offers more than 7,000 square meters of clinical and commercial manufacturing capacity.

Founded more than 20 years ago, the business has about 400 employees with substantial operational and technical expertise in a broad range of viral vector classes, and estimated 2020 revenue of 80 million euros, or about $95 million.

"Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally. The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America," said Michel Lagarde, executive vice president of Thermo Fisher.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chico's FAS Inc. (CHS) Tuesday reported a wider year-over-year net loss for the fourth quarter. Meanwhile, Kohl's Corp.'s (KSS) fourth-quarter net income grew 29 percent from the previous year. But Abercrombie & Fitch Co.'s (ANF) fourth-quarter net income decreased 1 percent from the prior year. The U.S. Food and Drug Administration has approved the marketing of a new robotically-assisted surgical device (RASD) that can facilitate transvaginal hysterectomy in certain patients using minimally-invasive surgical instruments. The Hominis Surgical System of Memic Innovative Surgery Ltd., the U.S. subsidiary of Israeli biotechnology company memic Ltd., has been granted marketing authorization. Canadian cannabis company Canopy Growth Corp. (CGC, WEED.TO) announced Tuesday the launch of its Cannabidiol (CBD) beverage brand Quatreau in the high-potential U.S. market. Quatreau will be sold on Canopy's one-stop U.S. e-commerce destination, www.shopcanopy.com. Quatreau is a premium ready-to-drink...
Follow RTT